La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Roche Holding Dividendo

Dividendo criteri di controllo 5/6

Roche Holding è una società che paga dividendi con un rendimento attuale pari a 3.39%, ben coperto dagli utili.

Informazioni chiave

3.5%

Rendimento del dividendo

72%

Rapporto di remunerazione

Rendimento medio del settore	2.3%
Prossima data di pagamento dei dividendi	n/a
Data di stacco del dividendo	n/a
Dividendo per azione	CHF 9.600
Utile per azione	CHF 13.33
Previsione del rendimento del dividendo	3.8%

Aggiornamenti recenti sui dividendi

Roche Holding's (VTX:ROG) Shareholders Will Receive A Bigger Dividend Than Last Year

Mar 06

Roche Holding's (VTX:ROG) Shareholders Will Receive A Bigger Dividend Than Last Year

Feb 09

Recent updates

These 4 Measures Indicate That Roche Holding (VTX:ROG) Is Using Debt Reasonably Well

Sep 10

We Think Roche Holding (VTX:ROG) Can Stay On Top Of Its Debt

Apr 17

Roche Holding's (VTX:ROG) Shareholders Will Receive A Bigger Dividend Than Last Year

Mar 06

Roche Holding's (VTX:ROG) Shareholders Will Receive A Bigger Dividend Than Last Year

Feb 09

Stabilità e crescita dei pagamenti

Recupero dei dati sui dividendi

Dividendo stabile: I dividendi per azione di ROG sono rimasti stabili negli ultimi 10 anni.

Dividendo in crescita: I pagamenti dei dividendi di ROG sono aumentati negli ultimi 10 anni.

Rendimento dei dividendi rispetto al mercato

Roche Holding Rendimento dei dividendi rispetto al mercato

Come si colloca il rendimento da dividendo di ROG rispetto al mercato?
Segmento	Rendimento dei dividendi
Azienda (ROG)	3.5%
Fondo del 25% del mercato (CH)	1.8%
Top 25% del mercato (CH)	4.3%
Media del settore (Pharmaceuticals)	2.3%
Analista previsionale (ROG) (fino a 3 anni)	3.8%

Dividendo notevole: Il dividendo di ROG ( 3.39% ) è più alto rispetto al 25% inferiore dei pagatori di dividendi nel mercato Swiss ( 1.88% ).

Dividendo elevato: Il dividendo di ROG ( 3.39% ) è basso rispetto al 25% dei maggiori pagatori di dividendi nel mercato Swiss ( 4.3%.

Distribuzione degli utili agli azionisti

Copertura degli utili: Grazie al suo ragionevole payout ratio ( 72.1% ), i pagamenti dei dividendi di ROG sono coperti dagli utili.

Pagamenti in contanti agli azionisti

Copertura del flusso di cassa: Grazie al suo ragionevole cash payout ratio ( 67.4% ), i pagamenti dei dividendi di ROG sono coperti dai flussi di cassa.

Roche Holding Dividendo

Dividendo criteri di controllo 5/6

Informazioni chiave

Aggiornamenti recenti sui dividendi

Upcoming dividend of CHF9.60 per share

Roche Holding's (VTX:ROG) Shareholders Will Receive A Bigger Dividend Than Last Year

Roche Holding's (VTX:ROG) Shareholders Will Receive A Bigger Dividend Than Last Year

Roche Holding AG Proposes Dividend

Recent updates

Halozyme Therapeutics, Inc. Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO with ENHANZE for People with Relapsing and Primary Progressive Multiple Sclerosis

FDA Approves Roche’s Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy

These 4 Measures Indicate That Roche Holding (VTX:ROG) Is Using Debt Reasonably Well

Roche's Fenebrutinib Demonstrates Near- Complete Suppression of Disease Activity and Disability Progression for Up to 48 Weeks in Patients with Relapsing Multiple Sclerosis

Roche’s PiaSky Approves in the Eu as the First Monthly Subcutaneous Treatment for People with PNH

New minor risk - Earnings quality

European Commission Approves Roche’s Vabysmo for Treatment of Retinal Vein Occlusion (RVO)

First half 2024 earnings: EPS misses analyst expectations

Roche Holding AG Raises Earnings Guidance for the Year 2024

BioPharma Credit PLC Notes the Update on the UK CMA (Competition and Markets Authority) Regarding the CMA's Clearance of the Proposed Acquisition of LumiraDx by Roche

New Data for Roche’s Susvimo Demonstrates Sustained Efficacy in Two Serious Diabetic Eye Conditions

Health Canada Authorizes Alecensaro (Alectinib) as the First and Only Adjuvant Treatment for People with Alk-Positive Early-Stage Lung Cancer

Roche to Reintroduce Susvimo in the US for People with Neovascular Age-Related Macular Degeneration (nAMD)

Roche Provides Update on Phase II/III SKYSCRAPER-06 Study in Metastatic Non-Small Cell Lung Cancer

Roche Holding AG to Report Q2, 2024 Results on Jul 25, 2024

Roche Announces the European Commission Grants Marketing Authorisation for OCREVUS (Ocrelizumab) Subcutaneous for the Treatment of Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis

Roche Launches New Highly-Sensitive Test to More Easily Diagnostic Patients Who May Have B-Cell Lymphoma

Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma

Roche Holding AG Announces U.S. Food and Drug Administration Accepted the New Drug Application and Granted Priority Review to Inavolisib, an Investigational, Oral Therapy, in Combination with Palbociclib (Ibrance®) and Fulvestrant

Roche Announces Management and Board Committee Changes

Roche Receives FDA Device Designation for Blood Test Measuring Lp(a)

Roche Reports Positive Phase I Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People with Obesity

Roche Announces FDA Approval of One of the First HPV Self- Collection Solutions in the U.S., Expanding Access and Screening Options to Help Eliminate Cervical Cancer

Roche Holding AG Provides Earnings Guidance for the Year 2024

FDA Approves Roche’s Alecensa as the First Adjuvant Treatment for People with ALK-Positive Early-Stage Lung Cancer

Roche Holding AG Announces Data from the Phase III OCARINA II Study (S31.006) of OCREVUS®? (ocrelizumab)

We Think Roche Holding (VTX:ROG) Can Stay On Top Of Its Debt

Roche Receives FDA Breakthrough Device Designation for Blood Test to Support Early Alzheimer's Disease Diagnosis

Roche Receives FDA Approval for the First Molecular Test to Screen for Malaria in Blood Donors

Roche Holding AG, Annual General Meeting, Mar 12, 2024

Upcoming dividend of CHF9.60 per share

Roche Holding's (VTX:ROG) Shareholders Will Receive A Bigger Dividend Than Last Year

Roche and Alnylam Report Positive Topline Results from the Phase II KARDIA-2 Study in People with Hypertension

Roche Announces FDA Approves Xolair as First and Only Medicine for Children and Adults with One or More Food Allergies

Roche Launches Three New Factor Xa Inhibitor Coagulation Tests to Meet Growing Patient Need

Roche Holding's (VTX:ROG) Shareholders Will Receive A Bigger Dividend Than Last Year

Roche Holding's (VTX:ROG) Soft Earnings Are Actually Better Than They Appear

Full year 2023 earnings: EPS and revenues miss analyst expectations

Dividend increased to CHF9.60

Roche Announces New 72-Week Data from Two Global Phase III Studies, BALATON and COMINO, Evaluating Vabysmo® (Faricimab) in Macular Edema Due to Branch and Central Retinal Vein Occlusion (BRVO and CRVO)

Roche Holding AG Proposes Dividend

Roche Holding AG (SWX:ROG) completed the acquisition of Carmot Therapeutics Inc. from a group of shareholders.

Roche Holding AG (SWX:ROG) completed the acquisition of Carmot Therapeutics Inc. from a group of shareholders.

European Commission Approves Roche's Tecentriq SC, the EU's First PD-(L)1 Cancer Immunotherapy Subcutaneous Injection for Multiple Cancer Types

Market Cool On Roche Holding AG's (VTX:ROG) Earnings

Roche Holding AG to Report Fiscal Year 2023 Results on Feb 01, 2024

Roche Announces New Data from Its CD20xCD3 T-Cell Engaging Bispecific Antibody Programme Were Presented At the 65Th American Society of Hematology Annual Meeting & Exposition

Roche Announces New Data Reinforce the Benefit of Early Preventative Treatment with Hemlibra for Babies with Severe Haemophilia A

Roche Presents Positive Results from the Phase III INAVO120 Study Evaluating Inavolisib in Combination with Palbociclib and Fulvestrant as a First-Line Treatment for People with PIK3CA-Mutation

We Think Roche Holding (VTX:ROG) Can Stay On Top Of Its Debt

Roche Holding AG (SWX:ROG) entered into a definitive merger agreement to acquire Carmot Therapeutics Inc. from a group of shareholders for approximately $2.7 billion.

Roche Expands Hepatitis Diagnostics Portfolio to Help Clinicians Diagnose and Monitor Patients with Acute or Chronic Hepatitis B Infection

Roche Expands Hepatitis Diagnostics Portfolio to Help Clinicians Diagnose and Monitor Patients with Acute or Chronic Hepatitis B Infection

Roche Launches Automated Serology Hepatitis E Virus Tests, Including A Test to Detect Acute Hev Infections, Recommended in the New Who 2023 Essential Diagnostics List

Roche's Subcutaneous Injection of Tecentriq Recommends by the EU's CHMP for Multiple Cancer Types

Roche Announces its Elecsys NfL Test Receives FDA Breakthrough Device Designation from the U.S. Food and Drug Administration

Roche Announces EMBARK Trial in Duchenne Muscular Dystrophy

United States Food and Drug Administration Approves Roche's Vabysmo for the Treatment of Retinal Veinocclusion (RVO)

Roche Holding AG Confirms Outlook for 2023

Roche Announces Roche IL-6 Is the First Immunoassay Approved to Aid Sepsis Diagnosis in Newborns

Roche Announces New Clinical and Real-World Data for Orevus (Ocrelizumab)

Roche Holding AG Announces Late-Breaking Data from the Phase III Ocarina III Study as an Investigational Twice-Yearly, 10-Minute Subcutaneous Injection on Pharmacokinetic, Biomarker, and Mri Measures in Patients with Relapsing or Primary Progressive Multiple Sclerosis

Roche Presents Positive Results from the Primary Analysis of the Ongoing Rainbowfish Study Assessing the Efficacy and Safety of Evrysdi

Roche and Alnylam Report Positive Topline Results from Phase 2 Study Kardia-1 of Zilebesiran

Stabilità e crescita dei pagamenti

Rendimento dei dividendi rispetto al mercato

Distribuzione degli utili agli azionisti

Pagamenti in contanti agli azionisti

Scoprire le società che pagano dividendi forti